Last reviewed · How we verify

NCT04441372: PRIORITISE

Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection

Status unknown Last updated 1 October 2021
What this trial tests

trial in SARS-CoV2 in 600 participants. Status unknown.

Timeline
1 October 2020
Primary endpoint
1 December 2021
1 December 2021

Quick facts

Lead sponsorMedecins Sans Frontieres, Spain
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment600
Start date1 October 2020
Primary completion1 December 2021
Estimated completion1 December 2021
Sites3 locations across Brazil, India

Conditions studied

Sponsor

Medecins Sans Frontieres, Spain

Who can join

18 and older, any sex, with SARS-CoV2 or COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Note that this is a study that is co-sponsored by Medecins Sans Frontieres, Spain, and the University of Oxford. The primary objective of this study is to identify clinical and biochemical prognostic markers in adults with virologically confirmed COVID-19 who do not require oxygen supplementation, with a focus on: aiding safe discharge from a healthcare facility (i.e. a high NPV); near-term impact on COVID-19 interventions in resource-limited settings (i.e. simple clinico-demographic variables and biochemical markers for which near-patient / POCTs are commercially available or in late-stage development). The secondary objective of this study is to evaluate the field-based performance of near-patient lateral flow assays for suPAR and IL-6 in adults with non-severe SARS-CoV-2 infection

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Facilitating Safe Discharge Through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study to Develop and Validate a Clinical Prediction Model in Resource-Limited Settings.
    Chandna A, Mahajan R, Gautam P, Mwandigha L, et al · · 2022 · cited 10× · PMID 35323932 · DOI 10.1093/cid/ciac224
  2. Host Biomarkers Reflect Prognosis in Patients Presenting With Moderate Coronavirus Disease 2019: A Prospective Cohort Study.
    Chandna A, Mahajan R, Gautam P, Mwandigha L, et al · · 2022 · cited 4× · PMID 36320192 · DOI 10.1093/ofid/ofac526
  3. Point-of-care prognostication in moderate Covid-19: Analytical validation and prognostic accuracy of a soluble urokinase plasminogen activator receptor (suPAR) rapid test.
    Chandna A, Mahajan R, Gautam P, Mwandigha L, et al · · 2023 · cited 2× · PMID 37603548 · DOI 10.1371/journal.pgph.0001538
  4. Point-of-care prognostication in moderate Covid-19: analytical validation and diagnostic accuracy of a soluble urokinase plasminogen activator receptor (suPAR) rapid test
    Chandna A, Mahajan R, Gautam P, Mwandigha L, et al · · 2022 · DOI 10.1101/2022.11.25.22282755
  5. Facilitating safe discharge through predicting disease progression in moderate COVID-19: a prospective cohort study to develop and validate a clinical prediction model in resource-limited settings
    Chandna A, Mahajan R, Gautam P, Mwandigha L, et al · · 2021 · DOI 10.1101/2021.12.02.21267170

Verify or expand the search:

Other Medecins Sans Frontieres, Spain trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04441372.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing